Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Assets Average (2021 - 2025)

Lyell Immunopharma (LYEL) has disclosed Assets Average for 5 consecutive years, with $374.0 million as the latest value for Q4 2025.

  • Quarterly Assets Average fell 32.62% to $374.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $374.0 million through Dec 2025, down 32.62% year-over-year, with the annual reading at $415.5 million for FY2025, 33.04% down from the prior year.
  • Assets Average hit $374.0 million in Q4 2025 for Lyell Immunopharma, down from $396.7 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.2 billion in Q3 2021 to a low of $374.0 million in Q4 2025.
  • Historically, Assets Average has averaged $781.2 million across 5 years, with a median of $793.8 million in 2023.
  • Biggest five-year swings in Assets Average: decreased 17.34% in 2023 and later tumbled 39.54% in 2025.
  • Year by year, Assets Average stood at $1.2 billion in 2021, then dropped by 17.67% to $957.4 million in 2022, then fell by 19.31% to $772.5 million in 2023, then dropped by 28.15% to $555.0 million in 2024, then plummeted by 32.62% to $374.0 million in 2025.
  • Business Quant data shows Assets Average for LYEL at $374.0 million in Q4 2025, $396.7 million in Q3 2025, and $407.6 million in Q2 2025.